<DOC>
	<DOCNO>NCT02376452</DOCNO>
	<brief_summary>This study design compare efficacy safety two-weekly RAILIRI regimen FOLFIRI regimen treatment advance colorectal cancer patient second-line setting .</brief_summary>
	<brief_title>Phase II Study 2-weekly RAILIRI Versus FOLFIRI Second-line Treatment Advanced Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>age 1870 year histologically cytologically confirm advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status 0 1 life expectancy â‰¥ 3 month patient fail firstline treatment either XELOX ( capecitabine combine oxaliplatin ) FOLFOX ( 5fluorouracil/leucovorin oxaliplatin ) least one measurable disease lesion accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) criterion adequate bone marrow , hepatic , renal function patient previous chronic inflammatory bowel disease , chronic diarrhea recurrent bowel obstruction patient symptomatic brain metastasis active clinical severe infection previously receive irinotecan raltitrexed dihydropyrimidine dehydrogenase ( DPD ) enzyme adequate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>